,44 Objective response rates for a range of DC vaccines loaded with antigens, such as tyrosinase, gp100, MART-1, and MAGE-A3, and autologous peptides in melanoma patients did not exceed 5%–10%.45 Here, MAGEA3 is linked to melanoma.